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Abstract
Objective. To examine effects of pre-enrollment opi-
oid use on outcomes of a 12-month collaborative
pain care management trial. We hypothesized that
participants with opioid use would have worse pain
at baseline; use more health care services and anal-
gesics; and have worse pain outcomes during the
trial.
Design. Secondary analysis of randomized con-
trolled trial data.
Setting. Veterans Affairs (VA) primary care.
Subjects. Patients age 18-65 years with chronic pain
of at least moderate severity who were enrolled in a
12-month pragmatic trial of a telephone-based col-
laborative care intervention for chronic musculo-
skeletal pain.
Methods. Participants were categorized as opioid
users (n¼ 84) or non-users (n¼ 166) at baseline
and trial randomization was stratified by opioid
use. We used logistic regression to examine
cross-sectional associations with baseline opioid
use and mixed-effect models for repeated meas-
ures to examine baseline opioid use as a predictor
of Brief Pain Inventory (BPI) scores over 12
months.
Results. At baseline, 33.6% reported use of pre-
scribed opioids. Baseline opioid users had higher
baseline BPI scores and higher health-related dis-
ability than non-users. Baseline opioid users also
had more outpatient visits (15.0 vs. 10.1; p¼0.001)
and received more analgesics (p< 0.001) during the
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trial. In the final multivariable model examining ef-
fects of baseline opioid use on BPI over 12 months,
opioid users and nonusers had a non-significant dif-
ference of 0.25 points (p¼ 0.098). In conclusion, al-
though baseline opioid users had worse pain
at baseline and used more health care during
the study, response to the intervention was not
significantly modified by pre-existing opioid therapy.
Key Words. Chronic Pain; Opioid Analgesics;
Primary Care
Introduction
Controlled trials of long-term opioid therapy have not
been published, but observational studies of patients
with chronic pain have found associations of long-term
opioids with worse pain outcomes, including more se-
vere pain, functional disability, and psychological dis-
tress [1–6]. These observed associations may be
attributable, in part, to clinical decisions to reserve opi-
oid therapy for patients with higher levels of pain-related
distress and for those who fail to respond to first and
second-line pain treatments. However, it is also possible
that treatment with opioids may contribute to persist-
ence of pain by altering pain modulatory systems, rein-
forcing counterproductive pain behaviors, or interfering
with participation in non-opioid therapies.
We analyzed data from a 12-month pragmatic trial of a
telephone-based collaborative care intervention for pri-
mary care patients with chronic musculoskeletal pain
[7]. In this paper, we examine relationships of pre-enroll-
ment opioid use with baseline characteristics, health
care service use, and pain outcomes. Our specific ob-
jectives were to 1) describe patient factors associated
with pre-enrollment opioid use; 2) compare health care
service and analgesic use among pre-enrollment opioid
users and non-users over 12 months; and 3) examine
whether pre-enrollment opioid use predicted pain out-
comes or modified the intervention effect. Compared to
participants without pre-enrollment opioid use, we
hypothesized that participants with pre-enrollment opi-
oid use would have worse pain and more mental health
comorbidity at baseline, use more health care services
and analgesics, and have worse pain outcomes in re-
sponse to the active intervention.
Methods
The Stepped Care to Optimize Pain Care Effectiveness
(SCOPE) study was a 12-month pragmatic trial of a tele-
phone-based collaborative care intervention for primary
care patients with chronic musculoskeletal pain.
Descriptions of the SCOPE intervention, methods, and
main results have been previously published [7,8]. The
study was approved by the Indiana University
Institutional Review Board and VA Research Committee.
All participants provided written informed consent.
Participants and Setting
In brief, SCOPE participants were Veteran Affairs (VA) pri-
mary care patients, 18–65 years old, with musculoskel-
etal pain for at least 3 months and of at least moderate
severity, defined as average or worst pain intensity  5
on a 0–10 scale. Exclusion criteria were pending pain-
related disability claim, psychosis, cognitive impairment,
current illicit drug use, active suicidal ideation, and life ex-
pectancy < 12 months. Potentially eligible primary care
patients were identified by musculoskeletal pain ICD-9
diagnoses in the VA electronic medical record and invited
to participate through mail and telephone contacts.
Patients who consented to participate were randomized
to either the intervention or usual care. Of the 250 pa-
tients who were randomized, all provided data at baseline
and 249 provided data at 1 follow-up time point.
Intervention
Participants assigned to the intervention arm received 12
months of automated symptom monitoring and tele-
phone-based care management. Automated symptom
monitoring involved regular administration of a 15-item
survey covering pain, mood, and medication topics by
telephone interactive voice response or internet (depend-
ing on patient preference). Care management included
self-management support and analgesic optimization de-
livered by a nurse care manager and supervised by the
physician-investigator team (EEK, KK). Initial nurse care
management contacts were scheduled at baseline, 4
weeks, and 12 weeks; additional calls were prompted by
automated symptom monitoring alerts. The alerts were
triggered by reports of inadequate pain improvement,
medication non-adherence or side effects, desire to
change medication, or request for contact by the nurse
care manager. Analgesic optimization was guided by a
stepped care medication algorithm that focused primarily
on active adjustment of non-opioid medications.
Opioid Use at Baseline
Participants were interviewed about past and current anal-
gesic medication use at baseline and were categorized as
opioid users (n¼ 84) or non-users (n¼ 166) based on their
self-report of current medication use. Trial randomization
was stratified by current self-reported opioid use, so equal
numbers of opioid users were assigned to each trial arm
(i.e., n¼42 opioid users in the intervention arm and
n¼ 42 opioid users in the usual care arm). We reviewed
VA electronic medical records and confirmed recent pre-
scriptions consistent with participants’ self-report for 83 of
84 (98.8%) self-reported opioid users.
Measures
Outcome assessments were administered at baseline
and at 1, 3, 6, and 12 months. The primary outcome
was the total score on the Brief Pain Inventory (BPI)
over 12 months. The BPI is a validated pain outcome
measure with demonstrated responsiveness to change
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[9]. The BPI assesses pain intensity (4 items) and pain-
related functional interference (7 items) on 11-point nu-
meric rating scales [10]. Total scores range from 0-10,
with higher scores indicating worse pain. Additional pain
variables included location and duration of pain; pain
self-efficacy measured with the Arthritis Self Efficacy
Scale (ASES) [11]; and pain catastrophizing, measured
with the Coping Strategies Questionnaire (CSQ) cata-
strophizing subscale [12,13].
Probable major depression was assessed according to
the Patient Health Questionnaire 9-item depression scale
(PHQ-9) diagnostic algorithm [14]. Probable posttraumatic
stress disorder (PTSD) was defined as endorsement of 2
or more items on the 4-item Primary Care PTSD Screen
[15] and a score of at least 41 on the 17-item
Posttraumatic Stress Disorder Checklist, which has been
shown to represent clinically significant posttraumatic
stress [16]. Health-related disability days were determined
by asking patients: “During the past 4 weeks, how many
days did you cut down on the things you usually do for
one-half day or more because of your physical health or
emotional problems?” The number could range from 0 to
28, and high health-related disability was defined as14
days. Quality of life variables were assessed with Medical
Outcomes Study Short-Form 36 scales [17].
The 3-item version of the Alcohol Use Disorders
Identification Test (AUDIT-C) was used to assess poten-
tially hazardous alcohol use [18]. Substance use risk was
assessed with five questions about personal history of
substance use. Participants were asked about their life-
time use of 3 categories of substances: “1) medicine for
pain, sleep, or nerves that was prescribed for another
person; 2) marijuana; and 3) other street drugs (such as
cocaine, speed, meth, heroin)”. For each category, re-
sponse options were the following: never, more than 10
years ago, 1-10 years ago, 3-12 months ago, and within
the past 3 months. Participants were asked the following
two additional questions: 1) “In your lifetime, have you
ever had a problem with drugs or alcohol?” and 2) “have
you ever received treatment or counseling for a drug or
alcohol problem?.” Participants were classified as “low
risk” if answers to all 3 lifetime substance use questions
were “never” or “more than 10 years ago” and answers
to both personal history questions were “no.”
Health Care Service and Analgesic Use
Health care services and analgesic use over the 12
months of the trial were evaluated using the VA elec-
tronic medical record and pharmacy dispensing data.
Health care services were quantified as numbers of out-
patient visits (including primary care; specialty medicine;
specialty surgery; mental health; and other types), emer-
gency department (ED visits), and hospitalizations.
Analgesic use during the trial was described in terms of
“analgesic months,” the sum of months of each discrete
analgesic dispensed during the 12-month trial (for ex-
ample, a patient on analgesic A for 6 months, analgesic
B for 3 months, and analgesic C for 12 months would
have 21 analgesic months). Opioid use during the 12-
month trial was described as the number of months’
supply of opioids dispensed (range 0 to 12).
Statistical Analysis
We used chi-square and t-tests to compare the character-
istics of opioid users and non-users at baseline. To exam-
ine cross-sectional associations with baseline opioid use,
we used a multivariable logistic regression model.
Variables were included in the multivariable model if they
were theoretically related to opioid use or associated at
the p0.2 level in unadjusted comparisons. To examine
differences between baseline opioid users and non-users
in health care service use, the number of each type of visit
was compared using negative binomial regression models.
Wilcoxon rank sum tests were used to compare analgesic
and opioid months of opioid users versus non-users.
To examine baseline opioid use as a predictor of im-
provement in the BPI total score, the primary pain out-
come, we used mixed-effect models for repeated
measures (MMRM) with the BPI total score at 1, 3, 6, 12
months as the response variable and opioid use as the
main predictor. Data were available for 248 participants
at 1 month, 244 at 3 months, 245 at 6 months, and 238
at 12 months [7]. One participant did not provide any fol-
low-up data and was excluded from this analysis. A ran-
dom intercept was included to model the within-subject
correlation. The first model adjusted for intervention
group, BPI total score at baseline, and visit time; the se-
cond model added baseline covariates that had p<0.2
for independent association with opioid use in the base-
line multivariable model (i.e., current smoking status, high
health-related disability, and probable major depression).
To test whether opioid use modified the intervention ef-
fect on the primary outcome, an interaction term of opi-
oid use by treatment arm was included in the model;
because no significant interaction was found, the final
models did not include the interaction term.
Results
Overall, participants were 83% male and had a mean
age of 55.1 years (range 28–65). Self-reported race was
77% white, 19% black, and 4% other. The mean BPI
total score was 5.2 at baseline. Nearly all participants re-
ported pain duration of more than 1 year, with duration
of 1–5 years in 26.4% (n¼ 66), 6–10 years in 19.2%
(n¼ 48), and more than 10 years in 52.4% (n¼ 131).
At baseline, 84 (33.6%) participants reported use of pre-
scribed opioids. Of participants reporting opioid use at
baseline, 7 reported taking more than one opioid. When
opioid and opioid-combination analgesics were catego-
rized according to their opioid ingredient, the most com-
mon opioid was hydrocodone (n¼ 65, 77.4% of opioid
users); other opioids reported were oxycodone (n¼15,
17.9% of opioid users), morphine (n¼ 6, 7.1%), codeine
(n¼ 5, 6.0%), and fentanyl (n¼ 1, 1.2%). At baseline,
the mean number of prior analgesic medications was
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6.9 (SD 3.0) for opioid users and 5.3 (SD 3.6) for non-
users (p< 0.011 for between-group comparison).
Table 1 shows unadjusted baseline comparisons be-
tween opioid users and non-users. Opioid users had
worse baseline BPI total scores (6.2 vs. 4.7, p< 0.001),
more pain sites (5.5 vs. 4.6), and more medical comor-
bidities (2.3 vs. 1.9, p¼ 0.024) than non-users. Opioid
users were less likely to be employed (52.4 vs. 69.9%,
p¼ 0.003), more likely to have depression (42.9 vs.
14.5%, <0.001), more likely to smoke (35.7 vs. 19.9%,
p¼ 0.022), and more likely to have high health-related
Table 1 Characteristics of participants with and without opioid use at baseline
Variable Opioid use (n¼ 84) No opioid use (n¼ 166) P-value
Age in years, mean (SD) 55.2 (7.6) 55.2 (8.9) 0.97
Male, n (%) 67 (79.8) 140 (84.3) 0.37
Race, n (%) 0.36
White 68 (81.0) 124 (74.7)
Black 12 (14.3) 36 (21.7)
Other 4 (4.8) 6 (3.6)
Married, n (%) 61 (72.6) 124 (74.7) 0.72
Education, n (%) 0.97
 High school 22 (26.2) 43 (25.9)
Some college or trade school 43 (51.2) 83 (50.0)
College graduate 19 (22.6) 40 (24.1)
Employment, n (%) 0.003
Employed 44 (52.4) 116 (69.9)
Unemployed 22 (26.2) 17 (10.2)
Retired 18 (21.4) 33 (19.9)
Income adequacy by self-report, n (%) 0.009
Comfortable 32 (38.1) 95 (57.2)
Just enough to make ends meet 39 (46.4) 59 (35.5)
Not enough to make ends meet 13 (15.5) 12 (7.2)
Smoking, n (%) 0.022
Current 30 (35.7) 33 (19.9)
Past 31 (36.9) 71 (42.8)
Never 23 (27.4) 62 (37.4)
Number of medical comorbidities, mean (SD) 2.3 (1.5) 1.9 (1.3) 0.033
High health-related disability, n (%) 45 (53.6) 35 (21.1) <0.001
Pain variables
BPI total score, mean (SD) 6.2 (1.4) 4.7 (1.8) <0.001
Duration of pain in years, n (%) 0.61
 5 22 (26.2) 51 (30.7)
6-10 15 (17.9) 33 (19.9)
> 10 47 (56.0) 82 (49.4)
Number of pain sites, mean (SD) 5.5 (3.2) 4.6 (2.8) 0.024
ASES pain self-efficacy score, mean (SD) 5.5 (2.4) 6.6 (1.9) <0.001
CSQ pain catastrophizing score, mean (SD) 14.5 (9.5) 9.5 (7.1) <0.001
Mental health variables
Probable major depression, n (%) 36 (42.9) 24 (14.5) <0.001
Probable PTSD, n (%) 22 (26.2) 21 (12.7) 0.007
Potentially hazardous alcohol use, n (%) 19 (22.6) 43 (25.9) 0.57
Substance use risk > low, n (%) 39 (46.4) 61 (36.8) 0.14
Quality of life variables
SF-36 general health perceptions 40.7 (29.2) 56.6 (27.5) <0.001
SF-36 social functioning 58.6 (29.2) 70.9 (25.2) 0.001
SF-36 vitality [0-100] 34.2 (22.8) 43.8 (21.9) 0.002
ASES ¼ Arthritis Self Efficacy Scale score (range 1–10; higher scores are better); BPI ¼ Brief Pain Inventory (range 0–10, lower
scores are better); CSQ ¼ Coping Strategies Questionnaire catastrophizing subscale (range 0–36; lower scores are better);
PTSD ¼ Post-Traumatic Stress Disorder; SF-36 Medical Outcomes Study Short-Form 36 (range 0-100; higher scores are
better).
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disability (53.6 vs. 21.1%, <0.001). Table 2 shows re-
sults of the multivariable model examining baseline as-
sociations with opioid use. In this model, only baseline
BPI scores and high health-related disability were inde-
pendently associated with baseline opioid use. Each
additional point on the BPI total score was associated
with a 41% higher odds of opioid use (OR¼1.41, 95%
CI: 1.11, 1.80) and high health-related disability was
associated with more than twice the likelihood of opioid
use (OR¼2.11, 95% CI: 1.05, 4.24).
Health Care Service and Analgesic Use
Table 3 shows health care visits and analgesic use dur-
ing the 12 month trial. Compared with opioid non-users,
baseline opioid users had more outpatient visits overall
(15.0 (SD 14.0) vs. 10.1 (SD 11.0); p¼ 0.001), more
emergency department visits (0.5 (SD 1.2) vs. 0.3 (SD
0.7); p¼ 0.042), and no significant difference in the
number of hospitalizations (0.1 (SD 0.3) vs. 0.03 (SD
0.2); p¼ 0.07). Over the 12-month trial, baseline opioid
users received more overall analgesic months (12.7 (SD
9.2) months) than non-users (4.9 (SD 4.8) months;
p<0.001 for between-group comparison). Baseline opi-
oid users also received more months of opioids during
the trial than non-users (4.7 (SD 5.5) vs. 0.3 (SD 1.4)
months; p< 0.001 for between-group comparison).
Among participants assigned to the intervention group
(n¼ 124), opioid users had more contacts with the nurse
care manager (mean 15.5 (SD 7.3) vs. 11.3 (SD 4.5) con-
tacts, p< 0.001) and generated more alerts from the
automated symptom monitoring system (mean 8.6 (SD
4.7) vs. 5.6 (SD 4.0) alerts, p¼ 0.001) than non-users.
Pain Severity over 12 Months
Table 4 shows unadjusted mean BPI scores at each as-
sessment time point for the opioid use and no opioid use
groups. Mean scores decreased over time in both groups,
from 6.20 at baseline to 5.07 at 12 months in the opioid
use group and from 4.72 at baseline to 3.61 at 12 months
in the no opioid group. Table 5 displays results of the mul-
tivariable models examining opioid use as a predictor of
improvement in pain severity (i.e., the BPI total score) over
12 months. In this table, negative beta coefficient values
indicate greater improvement in BPI over time. A test for
interaction of baseline opioid use with treatment group as-
signment was not statistically significant (p¼ 0.95), so no
interaction term was included in final longitudinal models.
In model 1, which controlled for baseline BPI, intervention
group, and time, the difference between opioid users and
non-users was a non-significant difference of 0.27 points
in BPI total score over 12 months (p¼ 0.059). In model 2,
which additionally controlled for smoking, health-related
disability, and depression, the difference between opioid
users and non-users was a non-significant difference of
0.25 points on the BPI total score (p¼ 0.098). In contrast,
treatment group assignment, baseline BPI total score, and
time were all highly significant independent predictors of
the pain severity outcome (all p< 0.001). As expected,
higher baseline BPI predicted less improvement in BPI
over 12 months, whereas assignment to the active inter-
vention group and time in the study were associated with
greater improvement in BPI.
Discussion
Consistent with our hypotheses, participants with opioid
use at the time of enrollment had worse baseline pain
and health-related disability at baseline and used more
health services and analgesics over 12 months.
Contrary to our hypothesis, baseline opioid use did not
modify the intervention’s positive effect on pain nor sig-
nificantly predict improvement in pain outcomes over
the 12 month study period.
Results of our unadjusted cross-sectional analyses are
consistent with prior studies, which have reported that,
among patients with pain, those treated with opioids
have worse pain severity, worse quality of life, more
health-related disability, more unemployment, more
mental health disorders, and more tobacco use than
those who are not treated with opioids [1–6]. In our mul-
tivariable baseline analysis, only baseline pain and
health-related disability were independently associated
with pre-enrollment opioid use. Associations with smok-
ing and probable depression were not statistically signifi-
cant in the cross-sectional multivariable model, but
Table 2 Independent associations of baseline
characteristics with baseline opioid use (n¼ 250)
Variable OR 95% CI P-value
Brief Pain Inventory
total score
1.41 (1.11, 1.80) 0.006
High health-related
disability
2.11 (1.05, 4.24) 0.036
Current smoking 1.82 (0.92, 3.60) 0.088
Probable major
depression
2.06 (0.90, 4.72) 0.089
Income < comfortable 1.43 (0.76, 2.70) 0.265
Number of pain sites 1.04 (0.94, 1.16) 0.431
Unemployed 1.37 (0.58, 3.23) 0.473
Probable PTSD 0.86 (0.36, 2.09) 0.746
Number of medical
comorbidities
1.03 (0.81, 1.30) 0.816
CSQ pain catastrophizing
score
0.99 (0.95, 1.05) 0.817
Substance use risk > low 1.04 (0.55, 1.95) 0.907
ASES pain self-efficacy
score
1.00 (0.84, 1.19) 0.975
ASES ¼ Arthritis Self Efficacy Scale score (range 1–10;
higher scores are better); BPI ¼ Brief Pain Inventory (range
0–10, lower scores are better); CSQ ¼ Coping Strategies
Questionnaire catastrophizing subscale (range 0-36; lower
scores are better); PTSD ¼ Post-Traumatic Stress Disorder;
SF-36 Medical Outcomes Study Short-Form 36 (range 0–100;
higher scores are better).
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given the wide confidence intervals, this may have been
due to our relatively small sample size.
Also consistent with prior research [4,19,20], we found
that participants with opioid use at the time of enrollment
used more health care services—including 50% more
outpatient visits—during the 12-month trial than those
without opioid use. This increased service use did not
appear to be attributable to a single type of service, but
rather appears relatively consistent across various types
of health care services. We did not assess reasons for
health care services use, so this greater use could be
due to greater pain-related distress or more co-morbidity
among participants with opioid use.
Mean BPI scores were higher in the opioid use group,
compared with the no opioid use group, at each time
point; however, the magnitude of improvement during
the course of the 12-month trial was similar for both
groups. In multivariable models, p-values for pre-enroll-
ment opioid use as a predictor of pain improvement
over the course of the 12-month trial were close to stat-
istical significance (0.059 and 0.098 in the basic and
fully-adjusted models). Regardless of statistical
significance, the size of the difference in BPI change be-
tween users and non-users was <0.30 points on a 0-
10 scale, which is unlikely to be clinically important. For
context, a difference of 1.0 in BPI score has been
suggested as a benchmark for minimally clinically im-
portant difference [21].
We are encouraged by our finding that patients’ re-
sponse to the collaborative pain management interven-
tion was not significantly modified by pre-existing opioid
therapy. Although patients on opioids were more dis-
tressed at baseline, they were still able to benefit from a
relatively low-intensity telephone-based intervention
involving symptom monitoring and active optimization of
non-opioid analgesics. This may be because, in most
cases, non-opioid analgesic options had not been ex-
hausted prior to opioid prescribing.
Table 3 12-month health care service and analgesic use according to opioid use at baseline
Variable
Opioid use (84) No opioid use (166)
P-value*Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Health care services
Outpatient visits, n
Total visits 15.0 (14.0) 10 (4–23) 10.1 (11.0) 7 (4–14) 0.001
Primary care physician 2.7 (2.1) 2 (2–3) 2.2 (1.6) 2 (1–3) 0.045
Primary care other‡ 0.9 (1.8) 0 (0–1) 1.0 (2.1) 1 (0–2) 0.62
Medical specialty 3.1 (4.6) 1 (0–5) 1.1 (1.8) 0 (0–1) <0.001
Surgical specialty 1.2 (2.8) 0 (0–1) 1.0 (2.0) 0 (0–1) 0.49
Mental health 2.6 (5.3) 0 (0–3) 1.7 (4.5) 0 (0–1) 0.25
Other¶ 4.4 (6.8) 1.5 (0–6) 3.0 (4.5) 1 (0–4) 0.06
ED visits, n 0.5 (1.2) 0 (0–0.5) 0.3 (0.7) 0 (0–0) 0.04
Hospitalizations, n 0.10 (0.3) 0 (0–0) 0.03 (0.2) 0 (0–0) 0.07
Hospital days, n 0.30 (1.2) 0 (0–0) 0.13 (1.0) 0 (0–0) 0.38
Analgesics
Number of analgesics 3.4 (1.6) 3 (2–4) 1.7 (1.5) 1 (1–2) <0.001
Analgesic months† 12.7 (9.2) 10 (7–18) 4.9 (4.8) 3 (1–8) <0.001
Opioid months 4.7 (5.5) 3 (1.5–5) 0.3 (1.4) 0 (0–0) <0.001
*Negative binomial distribution regression analysis was used to test between-group differences for all variables, except for anal-
gesic months, which were compared using Wilcoxon rank sum scores.
†Analgesic months is the sum of the number of months on each discrete analgesic during the 12-month trial. Opioid months is
the number of months on any opioid during the 12-month trial (range 0 to 12).
‡Primary care other ¼ non-physician visits to primary care clinics (e.g., nurse, pharmacist, nutritionist).
¶Other ¼ non-physician visits to non-primary care clinics (e.g., nurse, pharmacist, optometrist, physical or occupational therapist,
nutritionist).
ED¼ Emergency Department; SD¼ standard deviation. IQR¼ interquartile range (25th–75th percentile).
Table 4 Unadjusted Brief Pain Inventory (BPI)
total score among participants with and without
opioid use at baseline
BPI total score,
mean (SD)*
Opioid use
(n¼ 84)
No opioid use
(n¼166)
Baseline 6.20 (1.44) 4.72 (1.77)
1 month 5.52 (1.54) 4.33 (1.98)
3 months 5.50 (1.71) 4.03 (2.06)
6 months 5.27 (2.16) 3.80 (2.21)
12 months 5.07 (1.05) 3.61 (2.24)
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This trial was not designed to reduce or find alternatives
to opioid use. As all patients enrolling in the study had
at least moderate pain on their current therapy, many
study participants who were using opioids at baseline
may have been non-responders to opioid therapy and
potential candidates for opioid discontinuation, rotation,
or tapering; however, that was not an objective of the
study. There was no attempt to systematically reduce
opioid use in the intervention protocol. In fact, the inter-
vention and usual care groups did not differ in their opi-
oid use at baseline, during, or at the end of the trial.
The median daily dose in patients on opioids was 54 mg
morphine-equivalent mg at both baseline and 12
months [7]. We do not know whether including opioid
dose reduction or discontinuation in the intervention
protocol would have altered the results of this study.
Given growing evidence of harms associated with long-
term and high-dose opioid therapy [22–25], future re-
search should test the value of a similar intervention
model that included an opioid dose reduction protocol.
This study has several limitations. First, this is a secondary
analysis of a clinical trial that was not designed or powered
to answer these research questions. This analysis was
pre-planned and trial randomization was stratified by opi-
oid use so opioid users were equally distributed between
study arms. Second, the study was conducted in VA with
a predominantly male sample and the mean opioid daily
dose was in the moderate range; therefore, findings may
not be applicable to different clinical settings or to patients
receiving higher dose opioid therapy.
In summary, we found that response to a collaborative
pain management intervention involving analgesic opti-
mization was not significantly modified by pre-existing opi-
oid therapy. Future research should examine whether a
modified collaborative management protocol could be an
effective strategy to achieve dual goals of improving pain
outcomes and reducing intensity of opioid therapy.
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